Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy

BACKGROUND: Immune checkpoint blockades (ICBs) have emerged as a promising treatment for cancer. Recently, tumour mutational burden (TMB) and neoantigen load (NAL) have been proposed to be potential biomarkers to predict the efficacy of ICB; however, they were limited by difficulties in defining the...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Jiayue, Li, Xiangmei, He, Yalan, Wang, Qian, Li, Ji, Wu, Jiashuo, Jiang, Ying, Han, Junwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783967/
https://www.ncbi.nlm.nih.gov/pubmed/36564823
http://dx.doi.org/10.1186/s12967-022-03836-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783967/
https://www.ncbi.nlm.nih.gov/pubmed/36564823
http://dx.doi.org/10.1186/s12967-022-03836-3

Ejemplares similares